
|Articles|August 30, 2010
CN V3 Oncology Nurse - Related
Advertisement
Advertisement
Related Content
Advertisement

ByGiuseppe Curigliano,Joyce O'Shaughnessy, MD,François-Clément Bidard,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Lisa A. Carey, MD,Meena Okera,Everton Melo,Flora Zagouri,Manuel Ernesto Magallanes Maciel,Nuri Karadurmus,Shakeela Bahadur,Rebecca M Speck,Xuejing Aimee Wang,Suzanne Young,Komal L. Jhaveri,Nadia Harbeck, MD, PhD

102 Imlunestrant (imlu) With or Without Abemaciclib (abema) in Advanced Breast Cancer (ABC): Safety Analyses From the Phase III EMBER-3 Trial
ByJoyce O’Shaughnessy, MD,Francois Clement Bidard,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Philippe Aftimos,Cristina Saura,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,J A Garcia-Saenz,Maria Fernandez Abad,Larissa de Paula,Yeon Hee Park,Ozgur Ozyilkan,Maria Munoz,Sabrina Formentini,Emily Barrett,Shanshan Cao,Aarti Chawla,Komal L. Jhaveri



Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Investigational Radioenhancer Shows Feasibility in Stage III NSCLC
2
Subcutaneous Isatuximab May Optimize Multiple Myeloma Treatment Protocols
3
Mechanistic and Translational Insights of CARv3-TEAM-E in Glioblastoma
4
Toxicity From CD19, BCMA Therapy May Inform B-Cell Malignancy Surveillance
5


















































